Selected passages from the FDA letter
Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.
Passage 1The compounded semaglutide and tirzepatide products displayed on your website identify “Kin Meds” on the pictured label, suggesting Kin Meds is the compounder of those drugs when in fact it is not.
Passage 2“Same Active Ingredient as common brands”
Passage 3“Hit weight management goals with the same weight loss ingredient as brand-name GLP-1 medications, at a fraction of the cost”
Citations in the original letter
As cited in this historical letter, not a statement of current regulatory requirements.
- 21 CFR 201.1(h)(2)
- 21 CFR 201.1(a)